| OLAPARIB | Small molecule | Ewing sarcoma | PARP 1, 2 and 3 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| NIRAPARIB | Small molecule | prostate adenocarcinoma | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| NIRAPARIB | Small molecule | cancer | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Terminated | ClinicalTrials |
| TALAZOPARIB | Small molecule | prostate adenocarcinoma | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | colorectal carcinoma | PARP 1, 2 and 3 inhibitor | 2.0 | Completed | ClinicalTrials |
| NIRAPARIB TOSYLATE | Small molecule | peritoneal neoplasm | Poly [ADP-ribose] polymerase 2 inhibitor | 4.0 | - | FDA |
| NIRAPARIB | Small molecule | glioblastoma multiforme | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | prostate adenocarcinoma | PARP 1, 2 and 3 inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| VELIPARIB | Small molecule | gastric cancer | PARP 1, 2 and 3 inhibitor | 1.0 | Completed | ClinicalTrials |
| NIRAPARIB | Small molecule | urinary bladder cancer | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| VELIPARIB | Small molecule | cancer | PARP 1, 2 and 3 inhibitor | 2.0 | Completed | ClinicalTrials |
| VELIPARIB | Small molecule | endometrioid carcinoma | PARP 1, 2 and 3 inhibitor | 1.0 | Completed | ClinicalTrials |
| OLAPARIB | Small molecule | glioblastoma multiforme | PARP 1, 2 and 3 inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| VELIPARIB | Small molecule | Malignant Ovarian Brenner Tumor | PARP 1, 2 and 3 inhibitor | 1.0 | Completed | ClinicalTrials |
| OLAPARIB | Small molecule | ovarian cancer | PARP 1, 2 and 3 inhibitor | 3.0 | Recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | prostate cancer | PARP 1, 2 and 3 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| RUCAPARIB | Small molecule | Uterine Carcinosarcoma | PARP 1, 2 and 3 inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| VELIPARIB | Small molecule | colorectal carcinoma | PARP 1, 2 and 3 inhibitor | 2.0 | Completed | ClinicalTrials |
| SENAPARIB | Small molecule | small cell lung carcinoma | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| TALAZOPARIB TOSYLATE | Small molecule | non-small cell lung carcinoma | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| TALAZOPARIB | Small molecule | breast neoplasm | Poly [ADP-ribose] polymerase 2 inhibitor | 3.0 | Completed | ClinicalTrials |
| OLAPARIB | Small molecule | uterine leiomyosarcoma | PARP 1, 2 and 3 inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| NIRAPARIB | Small molecule | breast cancer | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| VELIPARIB | Small molecule | non-small cell lung carcinoma | PARP 1, 2 and 3 inhibitor | 1.0 | Terminated | ClinicalTrials |
| NIRAPARIB | Small molecule | ovarian cancer | Poly [ADP-ribose] polymerase 2 inhibitor | 4.0 | Active, not recruiting | ClinicalTrials |
| RUCAPARIB | Small molecule | ovarian cancer | PARP 1, 2 and 3 inhibitor | 2.0 | Completed | ClinicalTrials |
| OLAPARIB | Small molecule | prostate cancer | PARP 1, 2 and 3 inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| PAMIPARIB | Small molecule | grade II glioma | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | ovarian cancer | PARP 1, 2 and 3 inhibitor | 4.0 | Completed | ClinicalTrials |
| RUCAPARIB | Small molecule | prostate cancer | PARP 1, 2 and 3 inhibitor | 3.0 | Active, not recruiting | ClinicalTrials |
| TALAZOPARIB | Small molecule | acute myeloid leukemia | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| TALAZOPARIB | Small molecule | neoplasm | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| VELIPARIB | Small molecule | rectum cancer | PARP 1, 2 and 3 inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | uterine cancer | PARP 1, 2 and 3 inhibitor | 1.0 | Unknown status | ClinicalTrials |
| NIRAPARIB | Small molecule | ovarian cancer | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Completed | ClinicalTrials |
| OLAPARIB | Small molecule | prostate cancer | PARP 1, 2 and 3 inhibitor | 2.0 | Not yet recruiting | ClinicalTrials |
| NIRAPARIB | Small molecule | Ovarian Carcinosarcoma | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | breast carcinoma | PARP 1, 2 and 3 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| NIRAPARIB | Small molecule | prostate cancer | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| VELIPARIB | Small molecule | Hereditary breast and ovarian cancer syndrome | PARP 1, 2 and 3 inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| NIRAPARIB | Small molecule | ovarian cancer | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Not yet recruiting | ClinicalTrials |
| VELIPARIB | Small molecule | small cell lung carcinoma | PARP 1, 2 and 3 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| TALAZOPARIB | Small molecule | ovarian carcinoma | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| TALAZOPARIB | Small molecule | breast neoplasm | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Not yet recruiting | ClinicalTrials |
| RUCAPARIB | Small molecule | peritoneum cancer | PARP 1, 2 and 3 inhibitor | 1.0 | Completed | ClinicalTrials |
| NIRAPARIB | Small molecule | neoplasm | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| PAMIPARIB | Small molecule | biliary tract cancer | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Withdrawn | ClinicalTrials |
| OLAPARIB | Small molecule | pancreatic carcinoma | PARP 1, 2 and 3 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| TALAZOPARIB | Small molecule | breast cancer | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Terminated | ClinicalTrials |
| OLAPARIB | Small molecule | cutaneous melanoma | PARP 1, 2 and 3 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| VELIPARIB | Small molecule | squamous cell lung carcinoma | PARP 1, 2 and 3 inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| VELIPARIB | Small molecule | ovarian cancer | PARP 1, 2 and 3 inhibitor | 3.0 | Active, not recruiting | ClinicalTrials |
| NIRAPARIB | Small molecule | small cell lung carcinoma | Poly [ADP-ribose] polymerase 2 inhibitor | 3.0 | Terminated | ClinicalTrials |
| VELIPARIB | Small molecule | Hereditary breast and ovarian cancer syndrome | PARP 1, 2 and 3 inhibitor | 1.0 | Completed | ClinicalTrials |
| OLAPARIB | Small molecule | bladder tumor | PARP 1, 2 and 3 inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | fallopian tube cancer | PARP 1, 2 and 3 inhibitor | 2.0 | Withdrawn | ClinicalTrials |
| TALAZOPARIB | Small molecule | cancer | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| NIRAPARIB | Small molecule | ovarian cancer | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Not yet recruiting | ClinicalTrials |
| TALAZOPARIB | Small molecule | triple-negative breast cancer | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | prostate cancer | PARP 1, 2 and 3 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| TALAZOPARIB | Small molecule | acute myeloid leukemia | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Not yet recruiting | ClinicalTrials |
| TALAZOPARIB | Small molecule | squamous cell lung carcinoma | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| TALAZOPARIB | Small molecule | Fallopian Tube Serous Adenocarcinoma | Poly [ADP-ribose] polymerase 2 inhibitor | 0.5 | Completed | ClinicalTrials |
| VELIPARIB | Small molecule | Primary Peritoneal Serous Adenocarcinoma | PARP 1, 2 and 3 inhibitor | 1.0 | Completed | ClinicalTrials |
| NIRAPARIB TOSYLATE | Small molecule | Fallopian Tube Carcinoma | Poly [ADP-ribose] polymerase 2 inhibitor | 4.0 | - | FDA |
| RUCAPARIB | Small molecule | cancer | PARP 1, 2 and 3 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| NIRAPARIB | Small molecule | prostate adenocarcinoma | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | sarcoma | PARP 1, 2 and 3 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| TALAZOPARIB | Small molecule | angiosarcoma | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| VELIPARIB | Small molecule | Hereditary breast and ovarian cancer syndrome | PARP 1, 2 and 3 inhibitor | 2.0 | Withdrawn | ClinicalTrials |
| OLAPARIB | Small molecule | Central Nervous System Neoplasm | PARP 1, 2 and 3 inhibitor | 1.0 | Completed | ClinicalTrials |
| TALAZOPARIB | Small molecule | cancer | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Completed | ClinicalTrials |
| TALAZOPARIB | Small molecule | metastatic malignant neoplasm | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | carcinoma | PARP 1, 2 and 3 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| TALAZOPARIB | Small molecule | leukemia | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | breast cancer | PARP 1, 2 and 3 inhibitor | 2.0 | Terminated | ClinicalTrials |
| OLAPARIB | Small molecule | glioblastoma multiforme | PARP 1, 2 and 3 inhibitor | 0.5 | Not yet recruiting | ClinicalTrials |
| NIRAPARIB | Small molecule | HER2 Positive Breast Carcinoma | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | ovarian cancer | PARP 1, 2 and 3 inhibitor | 1.0 | Unknown status | ClinicalTrials |
| NIRAPARIB | Small molecule | mesothelioma | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | neoplasm | PARP 1, 2 and 3 inhibitor | 4.0 | - | ATC |
| OLAPARIB | Small molecule | metastatic melanoma | PARP 1, 2 and 3 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | metastatic prostate cancer | PARP 1, 2 and 3 inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| NIRAPARIB TOSYLATE | Small molecule | breast adenocarcinoma | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | non-small cell lung carcinoma | PARP 1, 2 and 3 inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| NIRAPARIB | Small molecule | peritoneal neoplasm | Poly [ADP-ribose] polymerase 2 inhibitor | 4.0 | - | FDA |
| OLAPARIB | Small molecule | cervical cancer | PARP 1, 2 and 3 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | germ cell tumor | PARP 1, 2 and 3 inhibitor | 2.0 | Unknown status | ClinicalTrials |
| OLAPARIB | Small molecule | Endometrial Serous Adenocarcinoma | PARP 1, 2 and 3 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| VELIPARIB | Small molecule | rectum cancer | PARP 1, 2 and 3 inhibitor | 1.0 | Completed | ClinicalTrials |
| NIRAPARIB | Small molecule | pancreatic ductal adenocarcinoma | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| VELIPARIB | Small molecule | Ovarian Carcinosarcoma | PARP 1, 2 and 3 inhibitor | 1.0 | Completed | ClinicalTrials |
| NIRAPARIB | Small molecule | Penile Carcinoma | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| TALAZOPARIB | Small molecule | prostate cancer | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Completed | ClinicalTrials |
| VELIPARIB | Small molecule | ovarian carcinoma | PARP 1, 2 and 3 inhibitor | 1.0 | Withdrawn | ClinicalTrials |
| VELIPARIB | Small molecule | ovarian clear cell adenocarcinoma | PARP 1, 2 and 3 inhibitor | 1.0 | Completed | ClinicalTrials |
| NIRAPARIB | Small molecule | lung cancer | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | primary peritoneal carcinoma | PARP 1, 2 and 3 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| NIRAPARIB | Small molecule | Fallopian Tube Carcinoma | Poly [ADP-ribose] polymerase 2 inhibitor | 4.0 | - | FDA |
| OLAPARIB | Small molecule | primary peritoneal carcinoma | PARP 1, 2 and 3 inhibitor | 1.0 | Terminated | ClinicalTrials |
| TALAZOPARIB | Small molecule | Hereditary breast and ovarian cancer syndrome | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Completed | ClinicalTrials |
| VELIPARIB | Small molecule | neoplasm | PARP 1, 2 and 3 inhibitor | 1.0 | Completed | ClinicalTrials |
| TALAZOPARIB | Small molecule | non-small cell lung carcinoma | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| NIRAPARIB | Small molecule | gastric cancer | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Terminated | ClinicalTrials |
| VELIPARIB | Small molecule | breast cancer | PARP 1, 2 and 3 inhibitor | 1.0 | Completed | ClinicalTrials |
| TALAZOPARIB | Small molecule | prostate adenocarcinoma | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| VELIPARIB | Small molecule | undifferentiated carcinoma | PARP 1, 2 and 3 inhibitor | 1.0 | Completed | ClinicalTrials |
| RUCAPARIB | Small molecule | biliary tract cancer | PARP 1, 2 and 3 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | breast carcinoma | PARP 1, 2 and 3 inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | cervical cancer | PARP 1, 2 and 3 inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | cancer | PARP 1, 2 and 3 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | metastatic prostate cancer | PARP 1, 2 and 3 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| NIRAPARIB | Small molecule | pancreatic carcinoma | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| NIRAPARIB | Small molecule | colorectal adenocarcinoma | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | pulmonary arterial hypertension | PARP 1, 2 and 3 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| PAMIPARIB | Small molecule | Central Nervous System Neoplasm | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Completed | ClinicalTrials |
| SENAPARIB | Small molecule | cancer | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Withdrawn | ClinicalTrials |
| PAMIPARIB | Small molecule | ovarian cancer | Poly [ADP-ribose] polymerase 2 inhibitor | 3.0 | Active, not recruiting | ClinicalTrials |
| NIRAPARIB | Small molecule | Hereditary breast and ovarian cancer syndrome | Poly [ADP-ribose] polymerase 2 inhibitor | 3.0 | Terminated | ClinicalTrials |
| OLAPARIB | Small molecule | neoplasm | PARP 1, 2 and 3 inhibitor | 1.0 | Completed | ClinicalTrials |
| TALAZOPARIB | Small molecule | breast cancer | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| NIRAPARIB | Small molecule | prostate cancer | Poly [ADP-ribose] polymerase 2 inhibitor | 3.0 | Active, not recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | endometrial cancer | PARP 1, 2 and 3 inhibitor | 0.5 | Not yet recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | primary peritoneal carcinoma | PARP 1, 2 and 3 inhibitor | 1.0 | Completed | ClinicalTrials |
| OLAPARIB | Small molecule | peritoneum cancer | PARP 1, 2 and 3 inhibitor | 2.0 | Withdrawn | ClinicalTrials |
| OLAPARIB | Small molecule | cancer | PARP 1, 2 and 3 inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | ovarian cancer | PARP 1, 2 and 3 inhibitor | 2.0 | Withdrawn | ClinicalTrials |
| NIRAPARIB | Small molecule | prostate cancer | Poly [ADP-ribose] polymerase 2 inhibitor | 3.0 | Recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | head and neck squamous cell carcinoma | PARP 1, 2 and 3 inhibitor | 2.0 | Completed | ClinicalTrials |
| TALAZOPARIB | Small molecule | triple-negative breast cancer | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| RUCAPARIB | Small molecule | ovarian cancer | PARP 1, 2 and 3 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| TALAZOPARIB | Small molecule | adrenal gland pheochromocytoma | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | non-small cell lung carcinoma | PARP 1, 2 and 3 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| NIRAPARIB | Small molecule | urothelial carcinoma | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Completed | ClinicalTrials |
| TALAZOPARIB | Small molecule | endometrial cancer | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | small cell lung carcinoma | PARP 1, 2 and 3 inhibitor | 3.0 | Recruiting | ClinicalTrials |
| E-7016 | Small molecule | melanoma | PARP 1, 2 and 3 inhibitor | 2.0 | Terminated | ClinicalTrials |
| NIRAPARIB | Small molecule | non-small cell lung carcinoma | Poly [ADP-ribose] polymerase 2 inhibitor | 3.0 | Recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | lung cancer | PARP 1, 2 and 3 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| RUCAPARIB | Small molecule | prostate cancer | PARP 1, 2 and 3 inhibitor | 2.0 | Completed | ClinicalTrials |
| TALAZOPARIB | Small molecule | metastatic prostate cancer | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | ovarian carcinoma | PARP 1, 2 and 3 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| NIRAPARIB | Small molecule | endometrial carcinoma | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| RUCAPARIB | Small molecule | fallopian tube cancer | PARP 1, 2 and 3 inhibitor | 3.0 | Active, not recruiting | ClinicalTrials |
| NIRAPARIB | Small molecule | ovarian clear cell cancer | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Not yet recruiting | ClinicalTrials |
| VELIPARIB | Small molecule | fallopian tube cancer | PARP 1, 2 and 3 inhibitor | 1.0 | Completed | ClinicalTrials |
| TALAZOPARIB | Small molecule | breast cancer | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Completed | ClinicalTrials |
| OLAPARIB | Small molecule | neoplasm | PARP 1, 2 and 3 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| RUCAPARIB | Small molecule | endometrial cancer | PARP 1, 2 and 3 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| PAMIPARIB | Small molecule | glioblastoma multiforme | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| NIRAPARIB | Small molecule | endometrial neoplasm | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | breast cancer | PARP 1, 2 and 3 inhibitor | 2.0 | Unknown status | ClinicalTrials |
| VELIPARIB | Small molecule | neoplasm | PARP 1, 2 and 3 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | small cell lung carcinoma | PARP 1, 2 and 3 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | ovarian cancer | PARP 1, 2 and 3 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| VELIPARIB | Small molecule | triple-negative breast cancer | PARP 1, 2 and 3 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| RUCAPARIB | Small molecule | prostate cancer | PARP 1, 2 and 3 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| TALAZOPARIB | Small molecule | endometrial cancer | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Withdrawn | ClinicalTrials |
| NIRAPARIB | Small molecule | metastatic prostate cancer | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Terminated | ClinicalTrials |
| OLAPARIB | Small molecule | gastric cancer | PARP 1, 2 and 3 inhibitor | 3.0 | Active, not recruiting | ClinicalTrials |
| TALAZOPARIB | Small molecule | endometrial cancer | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| NIRAPARIB | Small molecule | ovarian carcinoma | Poly [ADP-ribose] polymerase 2 inhibitor | 3.0 | Active, not recruiting | ClinicalTrials |
| PAMIPARIB | Small molecule | cancer | Poly [ADP-ribose] polymerase 2 inhibitor | 3.0 | Enrolling by invitation | ClinicalTrials |
| VELIPARIB | Small molecule | hepatocellular carcinoma | PARP 1, 2 and 3 inhibitor | 1.0 | Completed | ClinicalTrials |
| OLAPARIB | Small molecule | prostate carcinoma | PARP 1, 2 and 3 inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| TALAZOPARIB TOSYLATE | Small molecule | breast cancer | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Not yet recruiting | ClinicalTrials |
| VELIPARIB | Small molecule | anaplastic astrocytoma | PARP 1, 2 and 3 inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | urinary bladder cancer | PARP 1, 2 and 3 inhibitor | 2.0 | Completed | ClinicalTrials |
| OLAPARIB | Small molecule | pancreatic carcinoma | PARP 1, 2 and 3 inhibitor | 2.0 | Not yet recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | rhabdomyosarcoma | PARP 1, 2 and 3 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| NIRAPARIB | Small molecule | breast neoplasm | Poly [ADP-ribose] polymerase 2 inhibitor | 3.0 | Recruiting | ClinicalTrials |
| TALAZOPARIB | Small molecule | triple-negative breast cancer | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Not yet recruiting | ClinicalTrials |
| VELIPARIB | Small molecule | ovarian mucinous adenocarcinoma | PARP 1, 2 and 3 inhibitor | 1.0 | Completed | ClinicalTrials |
| PAMIPARIB | Small molecule | glioblastoma multiforme | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | breast neoplasm | PARP 1, 2 and 3 inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | urinary bladder carcinoma | PARP 1, 2 and 3 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | breast cancer | PARP 1, 2 and 3 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| SENAPARIB | Small molecule | prostate cancer | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Completed | ClinicalTrials |
| VELIPARIB | Small molecule | prostate cancer | PARP 1, 2 and 3 inhibitor | 1.0 | Completed | ClinicalTrials |
| OLAPARIB | Small molecule | Hereditary breast and ovarian cancer syndrome | PARP 1, 2 and 3 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | breast neoplasm | PARP 1, 2 and 3 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | bile duct cancer | PARP 1, 2 and 3 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| NIRAPARIB | Small molecule | ovarian cancer | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| RUCAPARIB | Small molecule | pancreatic ductal adenocarcinoma | PARP 1, 2 and 3 inhibitor | 2.0 | Completed | ClinicalTrials |
| PAMIPARIB | Small molecule | gastric cancer | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | squamous cell carcinoma | PARP 1, 2 and 3 inhibitor | 1.0 | Withdrawn | ClinicalTrials |
| NIRAPARIB | Small molecule | pancreatic carcinoma | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| RUCAPARIB | Small molecule | neoplasm | PARP 1, 2 and 3 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| VELIPARIB | Small molecule | pancreatic carcinoma | PARP 1, 2 and 3 inhibitor | 1.0 | Completed | ClinicalTrials |
| OLAPARIB | Small molecule | breast neoplasm | PARP 1, 2 and 3 inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| NIRAPARIB | Small molecule | ovarian neoplasm | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| TALAZOPARIB | Small molecule | breast cancer | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Not yet recruiting | ClinicalTrials |
| TALAZOPARIB TOSYLATE | Small molecule | neoplasm | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | ovarian carcinoma | PARP 1, 2 and 3 inhibitor | 4.0 | - | DailyMed |
| OLAPARIB | Small molecule | prostate adenocarcinoma | PARP 1, 2 and 3 inhibitor | 3.0 | Active, not recruiting | ClinicalTrials |
| NIRAPARIB | Small molecule | metastatic malignant neoplasm | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| PAMIPARIB | Small molecule | small cell lung carcinoma | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| TALAZOPARIB | Small molecule | non-small cell lung carcinoma | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Withdrawn | ClinicalTrials |
| OLAPARIB | Small molecule | endometrial neoplasm | PARP 1, 2 and 3 inhibitor | 3.0 | Recruiting | ClinicalTrials |
| VELIPARIB | Small molecule | cancer | PARP 1, 2 and 3 inhibitor | 2.0 | Withdrawn | ClinicalTrials |
| RUCAPARIB | Small molecule | ovarian cancer | PARP 1, 2 and 3 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | ovarian cancer | PARP 1, 2 and 3 inhibitor | 3.0 | Completed | ClinicalTrials |
| NIRAPARIB | Small molecule | cervical carcinoma | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | pulmonary arterial hypertension | PARP 1, 2 and 3 inhibitor | 0.5 | Terminated | ClinicalTrials |
| NIRAPARIB | Small molecule | endometrial cancer | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| NIRAPARIB | Small molecule | Hereditary breast and ovarian cancer syndrome | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| VELIPARIB | Small molecule | hepatocellular carcinoma | PARP 1, 2 and 3 inhibitor | 2.0 | Terminated | ClinicalTrials |
| PAMIPARIB | Small molecule | breast cancer | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Completed | ClinicalTrials |
| TALAZOPARIB | Small molecule | prostate cancer | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| RUCAPARIB | Small molecule | Hereditary breast and ovarian cancer syndrome | PARP 1, 2 and 3 inhibitor | 2.0 | Completed | ClinicalTrials |
| RUCAPARIB | Small molecule | leiomyosarcoma | PARP 1, 2 and 3 inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| RUCAPARIB | Small molecule | fallopian tube cancer | PARP 1, 2 and 3 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | carcinosarcoma | PARP 1, 2 and 3 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | malignant glioma | PARP 1, 2 and 3 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | Ewing sarcoma | PARP 1, 2 and 3 inhibitor | 2.0 | Completed | ClinicalTrials |
| NIRAPARIB | Small molecule | squamous cell carcinoma | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| VELIPARIB | Small molecule | Fallopian Tube Carcinosarcoma | PARP 1, 2 and 3 inhibitor | 1.0 | Completed | ClinicalTrials |
| OLAPARIB | Small molecule | breast cancer | PARP 1, 2 and 3 inhibitor | 3.0 | Active, not recruiting | ClinicalTrials |
| PAMIPARIB | Small molecule | prostate cancer | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Terminated | ClinicalTrials |
| SENAPARIB | Small molecule | ovarian cancer | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Completed | ClinicalTrials |
| TALAZOPARIB | Small molecule | primary peritoneal carcinoma | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Completed | ClinicalTrials |
| OLAPARIB | Small molecule | peritoneal neoplasm | PARP 1, 2 and 3 inhibitor | 3.0 | Active, not recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | breast cancer | PARP 1, 2 and 3 inhibitor | 2.0 | Not yet recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | ovarian carcinoma | PARP 1, 2 and 3 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | non-small cell lung carcinoma | PARP 1, 2 and 3 inhibitor | 3.0 | Recruiting | ClinicalTrials |
| PAMIPARIB | Small molecule | glioblastoma multiforme | Poly [ADP-ribose] polymerase 2 inhibitor | 0.5 | Recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | gastric cancer | PARP 1, 2 and 3 inhibitor | 1.0 | Not yet recruiting | ClinicalTrials |
| RUCAPARIB | Small molecule | peritoneum cancer | PARP 1, 2 and 3 inhibitor | 2.0 | Completed | ClinicalTrials |
| NIRAPARIB | Small molecule | peritoneum cancer | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Completed | ClinicalTrials |
| NIRAPARIB | Small molecule | lymphoma | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Withdrawn | ClinicalTrials |
| OLAPARIB | Small molecule | mesothelioma | PARP 1, 2 and 3 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | breast cancer | PARP 1, 2 and 3 inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | colorectal carcinoma | PARP 1, 2 and 3 inhibitor | 1.0 | Completed | ClinicalTrials |
| TALAZOPARIB | Small molecule | breast neoplasm | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | breast carcinoma | PARP 1, 2 and 3 inhibitor | 1.0 | Completed | ClinicalTrials |
| RUCAPARIB CAMSYLATE | Small molecule | neoplasm | PARP 1, 2 and 3 inhibitor | 1.0 | Completed | ClinicalTrials |
| OLAPARIB | Small molecule | malignant epithelial tumor of ovary | PARP 1, 2 and 3 inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| TALAZOPARIB | Small molecule | neoplasm | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | prostate cancer | PARP 1, 2 and 3 inhibitor | 3.0 | Active, not recruiting | ClinicalTrials |
| PAMIPARIB | Small molecule | grade III glioma | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | chronic lymphocytic leukemia | PARP 1, 2 and 3 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| RUCAPARIB | Small molecule | pancreatic carcinoma | PARP 1, 2 and 3 inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| TALAZOPARIB | Small molecule | pancreatic carcinoma | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Completed | ClinicalTrials |
| NIRAPARIB | Small molecule | breast cancer | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Completed | ClinicalTrials |
| TALAZOPARIB | Small molecule | ovarian cancer | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Terminated | ClinicalTrials |
| TALAZOPARIB | Small molecule | metastatic prostate cancer | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | glioblastoma multiforme | PARP 1, 2 and 3 inhibitor | 0.5 | Recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | small cell lung carcinoma | PARP 1, 2 and 3 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | non-small cell lung carcinoma | PARP 1, 2 and 3 inhibitor | 2.0 | Unknown status | ClinicalTrials |
| NIRAPARIB | Small molecule | cancer | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| TALAZOPARIB | Small molecule | ovarian cancer | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Completed | ClinicalTrials |
| VELIPARIB | Small molecule | small cell lung carcinoma | PARP 1, 2 and 3 inhibitor | 1.0 | Completed | ClinicalTrials |
| OLAPARIB | Small molecule | pancreatic carcinoma | PARP 1, 2 and 3 inhibitor | 2.0 | Unknown status | ClinicalTrials |
| TALAZOPARIB TOSYLATE | Small molecule | acute myeloid leukemia | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| VELIPARIB | Small molecule | metastatic melanoma | PARP 1, 2 and 3 inhibitor | 2.0 | Completed | ClinicalTrials |
| TALAZOPARIB | Small molecule | ovarian cancer | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Withdrawn | ClinicalTrials |
| PAMIPARIB | Small molecule | neoplasm | Poly [ADP-ribose] polymerase 2 inhibitor | 3.0 | - | ATC |
| OLAPARIB | Small molecule | prostate adenocarcinoma | PARP 1, 2 and 3 inhibitor | 2.0 | Terminated | ClinicalTrials |
| OLAPARIB | Small molecule | peritoneal neoplasm | PARP 1, 2 and 3 inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | biliary tract cancer | PARP 1, 2 and 3 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| RUCAPARIB | Small molecule | prostate cancer | PARP 1, 2 and 3 inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| PAMIPARIB | Small molecule | neoplasm | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| VELIPARIB | Small molecule | fallopian tube cancer | PARP 1, 2 and 3 inhibitor | 2.0 | Completed | ClinicalTrials |
| PAMIPARIB | Small molecule | grade II glioma | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | head and neck squamous cell carcinoma | PARP 1, 2 and 3 inhibitor | 1.0 | Withdrawn | ClinicalTrials |
| RUCAPARIB | Small molecule | prostate cancer | PARP 1, 2 and 3 inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | soft tissue sarcoma | PARP 1, 2 and 3 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | ovarian cancer | PARP 1, 2 and 3 inhibitor | 2.0 | Completed | ClinicalTrials |
| TALAZOPARIB | Small molecule | neoplasm | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| SENAPARIB | Small molecule | neoplasm | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Completed | ClinicalTrials |
| TALAZOPARIB | Small molecule | non-small cell lung carcinoma | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Completed | ClinicalTrials |
| RUCAPARIB | Small molecule | breast cancer | PARP 1, 2 and 3 inhibitor | 0.5 | Active, not recruiting | ClinicalTrials |
| VELIPARIB | Small molecule | breast cancer | PARP 1, 2 and 3 inhibitor | 3.0 | Completed | ClinicalTrials |
| OLAPARIB | Small molecule | small cell lung carcinoma | PARP 1, 2 and 3 inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| VELIPARIB | Small molecule | ovarian serous adenocarcinoma | PARP 1, 2 and 3 inhibitor | 1.0 | Completed | ClinicalTrials |
| NIRAPARIB | Small molecule | biliary tract neoplasm | Poly [ADP-ribose] polymerase 2 inhibitor | 3.0 | Not yet recruiting | ClinicalTrials |
| NIRAPARIB | Small molecule | head and neck malignant neoplasia | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| NIRAPARIB | Small molecule | ovarian cancer | Poly [ADP-ribose] polymerase 2 inhibitor | 3.0 | Active, not recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | prostate cancer | PARP 1, 2 and 3 inhibitor | 1.0 | Completed | ClinicalTrials |
| OLAPARIB | Small molecule | prostate carcinoma | PARP 1, 2 and 3 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | neuroendocrine neoplasm | PARP 1, 2 and 3 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| VELIPARIB | Small molecule | breast cancer | PARP 1, 2 and 3 inhibitor | 1.0 | Suspended | ClinicalTrials |
| NIRAPARIB | Small molecule | ovarian cancer | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| VELIPARIB | Small molecule | ovarian cancer | PARP 1, 2 and 3 inhibitor | 2.0 | Completed | ClinicalTrials |
| TALAZOPARIB | Small molecule | neoplasm | Poly [ADP-ribose] polymerase 2 inhibitor | 4.0 | - | ATC |
| TALAZOPARIB | Small molecule | breast neoplasm | Poly [ADP-ribose] polymerase 2 inhibitor | 4.0 | - | FDA |
| RUCAPARIB | Small molecule | ovarian cancer | PARP 1, 2 and 3 inhibitor | 3.0 | Active, not recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | endometrial cancer | PARP 1, 2 and 3 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| PAMIPARIB | Small molecule | head and neck squamous cell carcinoma | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Not yet recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | neoplasm | PARP 1, 2 and 3 inhibitor | 1.0 | Suspended | ClinicalTrials |
| RUCAPARIB | Small molecule | cervical cancer | PARP 1, 2 and 3 inhibitor | 2.0 | Withdrawn | ClinicalTrials |
| NIRAPARIB | Small molecule | small cell lung carcinoma | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| NIRAPARIB | Small molecule | ovarian cancer | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Completed | ClinicalTrials |
| NIRAPARIB | Small molecule | neoplasm | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Terminated | ClinicalTrials |
| VELIPARIB | Small molecule | small cell lung carcinoma | PARP 1, 2 and 3 inhibitor | 2.0 | Completed | ClinicalTrials |
| OLAPARIB | Small molecule | glioma | PARP 1, 2 and 3 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| NIRAPARIB | Small molecule | ovarian cancer | Poly [ADP-ribose] polymerase 2 inhibitor | 3.0 | Completed | ClinicalTrials |
| VELIPARIB | Small molecule | primary peritoneal carcinoma | PARP 1, 2 and 3 inhibitor | 1.0 | Completed | ClinicalTrials |
| OLAPARIB | Small molecule | carcinoma | PARP 1, 2 and 3 inhibitor | 3.0 | Active, not recruiting | ClinicalTrials |
| 2X-121 | Small molecule | neoplasm | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| VELIPARIB | Small molecule | Central Nervous System Neoplasm | PARP 1, 2 and 3 inhibitor | 1.0 | Completed | ClinicalTrials |
| OLAPARIB | Small molecule | pancreatic ductal adenocarcinoma | PARP 1, 2 and 3 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | acinar cell carcinoma | PARP 1, 2 and 3 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | colorectal carcinoma | PARP 1, 2 and 3 inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | prostate adenocarcinoma | PARP 1, 2 and 3 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| PAMIPARIB | Small molecule | ovarian cancer | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Not yet recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | breast carcinoma | PARP 1, 2 and 3 inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | endometrial carcinoma | PARP 1, 2 and 3 inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| NIRAPARIB | Small molecule | fallopian tube cancer | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Completed | ClinicalTrials |
| 2X-121 | Small molecule | ovarian cancer | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | high grade ovarian serous adenocarcinoma | PARP 1, 2 and 3 inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | neoplasm | PARP 1, 2 and 3 inhibitor | 2.0 | Not yet recruiting | ClinicalTrials |
| RUCAPARIB | Small molecule | peritoneum cancer | PARP 1, 2 and 3 inhibitor | 3.0 | Active, not recruiting | ClinicalTrials |
| PAMIPARIB | Small molecule | ovarian cancer | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| NIRAPARIB | Small molecule | neoplasm | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | fallopian tube cancer | PARP 1, 2 and 3 inhibitor | 3.0 | Active, not recruiting | ClinicalTrials |
| NIRAPARIB | Small molecule | endometrial cancer | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | cervical carcinoma | PARP 1, 2 and 3 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| RUCAPARIB | Small molecule | fallopian tube cancer | PARP 1, 2 and 3 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| TALAZOPARIB | Small molecule | central nervous system cancer | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| NIRAPARIB | Small molecule | nasopharyngeal neoplasm | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| RUCAPARIB CAMSYLATE | Small molecule | ovarian cancer | PARP 1, 2 and 3 inhibitor | 4.0 | - | DailyMed |
| OLAPARIB | Small molecule | cancer | PARP 1, 2 and 3 inhibitor | 1.0 | Unknown status | ClinicalTrials |
| NIRAPARIB | Small molecule | small cell lung carcinoma | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Not yet recruiting | ClinicalTrials |
| NIRAPARIB | Small molecule | uterine sarcoma | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| TALAZOPARIB | Small molecule | hematopoietic and lymphoid system neoplasm | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| NIRAPARIB | Small molecule | prostate cancer | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| VELIPARIB | Small molecule | primary peritoneal carcinoma | PARP 1, 2 and 3 inhibitor | 2.0 | Completed | ClinicalTrials |
| VELIPARIB | Small molecule | pancreatic carcinoma | PARP 1, 2 and 3 inhibitor | 1.0 | Unknown status | ClinicalTrials |
| OLAPARIB | Small molecule | cancer | PARP 1, 2 and 3 inhibitor | 1.0 | Completed | ClinicalTrials |
| OLAPARIB | Small molecule | ovarian cancer | PARP 1, 2 and 3 inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | ovarian cancer | PARP 1, 2 and 3 inhibitor | 3.0 | Enrolling by invitation | ClinicalTrials |
| OLAPARIB | Small molecule | pancreatic carcinoma | PARP 1, 2 and 3 inhibitor | 1.0 | Completed | ClinicalTrials |
| OLAPARIB | Small molecule | soft tissue sarcoma | PARP 1, 2 and 3 inhibitor | 3.0 | Recruiting | ClinicalTrials |
| VELIPARIB | Small molecule | breast cancer | PARP 1, 2 and 3 inhibitor | 2.0 | Completed | ClinicalTrials |
| TALAZOPARIB | Small molecule | ovarian cancer | Poly [ADP-ribose] polymerase 2 inhibitor | 3.0 | Completed | ClinicalTrials |
| OLAPARIB | Small molecule | head and neck squamous cell carcinoma | PARP 1, 2 and 3 inhibitor | 1.0 | Completed | ClinicalTrials |
| NIRAPARIB | Small molecule | leiomyosarcoma | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Not yet recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | small cell lung carcinoma | PARP 1, 2 and 3 inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | ovarian neoplasm | PARP 1, 2 and 3 inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | metastatic colorectal cancer | PARP 1, 2 and 3 inhibitor | 3.0 | Active, not recruiting | ClinicalTrials |
| NIRAPARIB | Small molecule | ovarian cancer | Poly [ADP-ribose] polymerase 2 inhibitor | 3.0 | Withdrawn | ClinicalTrials |
| RUCAPARIB | Small molecule | endometrial cancer | PARP 1, 2 and 3 inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| NIRAPARIB | Small molecule | neoplasm | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Completed | ClinicalTrials |
| OLAPARIB | Small molecule | non-small cell lung carcinoma | PARP 1, 2 and 3 inhibitor | 1.0 | Completed | ClinicalTrials |
| RUCAPARIB | Small molecule | ovarian cancer | PARP 1, 2 and 3 inhibitor | 4.0 | - | DailyMed |
| OLAPARIB | Small molecule | ovarian cancer | PARP 1, 2 and 3 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| TALAZOPARIB TOSYLATE | Small molecule | breast carcinoma | Poly [ADP-ribose] polymerase 2 inhibitor | 4.0 | - | FDA |
| OLAPARIB | Small molecule | metastasis | PARP 1, 2 and 3 inhibitor | 1.0 | Completed | ClinicalTrials |
| RUCAPARIB | Small molecule | breast cancer | PARP 1, 2 and 3 inhibitor | 2.0 | Completed | ClinicalTrials |
| TALAZOPARIB | Small molecule | prostate cancer | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Not yet recruiting | ClinicalTrials |
| TALAZOPARIB | Small molecule | colorectal carcinoma | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Completed | ClinicalTrials |
| OLAPARIB | Small molecule | ovarian cancer | PARP 1, 2 and 3 inhibitor | 4.0 | - | DailyMed |
| TALAZOPARIB | Small molecule | glioblastoma multiforme | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| VELIPARIB | Small molecule | neoplasm | PARP 1, 2 and 3 inhibitor | 3.0 | - | ATC |
| NIRAPARIB | Small molecule | breast cancer | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Not yet recruiting | ClinicalTrials |
| NIRAPARIB | Small molecule | ovarian cancer | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Unknown status | ClinicalTrials |
| TALAZOPARIB | Small molecule | small cell lung carcinoma | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | uterine leiomyosarcoma | PARP 1, 2 and 3 inhibitor | 2.0 | Not yet recruiting | ClinicalTrials |
| SENAPARIB | Small molecule | primary peritoneal carcinoma | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Completed | ClinicalTrials |
| OLAPARIB | Small molecule | carcinoma | PARP 1, 2 and 3 inhibitor | 1.0 | Unknown status | ClinicalTrials |
| RUCAPARIB | Small molecule | neoplasm | PARP 1, 2 and 3 inhibitor | 1.0 | Completed | ClinicalTrials |
| SENAPARIB | Small molecule | neoplasm | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Not yet recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | gastric adenocarcinoma | PARP 1, 2 and 3 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| NIRAPARIB | Small molecule | ovarian neoplasm | Poly [ADP-ribose] polymerase 2 inhibitor | 3.0 | Active, not recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | breast cancer | PARP 1, 2 and 3 inhibitor | 3.0 | Completed | ClinicalTrials |
| OLAPARIB | Small molecule | prostate cancer | PARP 1, 2 and 3 inhibitor | 2.0 | Completed | ClinicalTrials |
| TALAZOPARIB | Small molecule | neoplasm | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Completed | ClinicalTrials |
| TALAZOPARIB | Small molecule | neuroendocrine neoplasm | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | metastatic malignant neoplasm | PARP 1, 2 and 3 inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| NIRAPARIB | Small molecule | prostate adenocarcinoma | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Completed | ClinicalTrials |
| OLAPARIB | Small molecule | breast neoplasm | PARP 1, 2 and 3 inhibitor | 1.0 | Unknown status | ClinicalTrials |
| NIRAPARIB | Small molecule | breast cancer | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| NIRAPARIB | Small molecule | chronic lymphocytic leukemia | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Completed | ClinicalTrials |
| TALAZOPARIB | Small molecule | Primary Peritoneal Serous Adenocarcinoma | Poly [ADP-ribose] polymerase 2 inhibitor | 0.5 | Completed | ClinicalTrials |
| TALAZOPARIB | Small molecule | breast cancer | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | glioblastoma multiforme | PARP 1, 2 and 3 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| NIRAPARIB | Small molecule | breast cancer | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Not yet recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | breast cancer | PARP 1, 2 and 3 inhibitor | 1.0 | Terminated | ClinicalTrials |
| TALAZOPARIB | Small molecule | prostate cancer | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| 2X-121 | Small molecule | breast cancer | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| NIRAPARIB | Small molecule | metastatic melanoma | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| NIRAPARIB | Small molecule | ovarian neoplasm | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| VELIPARIB | Small molecule | metastatic malignant neoplasm | PARP 1, 2 and 3 inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | endometrium adenocarcinoma | PARP 1, 2 and 3 inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | lymphoma | PARP 1, 2 and 3 inhibitor | 1.0 | Withdrawn | ClinicalTrials |
| NIRAPARIB | Small molecule | breast cancer | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Withdrawn | ClinicalTrials |
| OLAPARIB | Small molecule | ovarian cancer | PARP 1, 2 and 3 inhibitor | 0.5 | Recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | triple-negative breast cancer | PARP 1, 2 and 3 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | mesothelioma | PARP 1, 2 and 3 inhibitor | 2.0 | Completed | ClinicalTrials |
| NIRAPARIB | Small molecule | neoplasm | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Not yet recruiting | ClinicalTrials |
| VELIPARIB | Small molecule | neoplasm | PARP 1, 2 and 3 inhibitor | 1.0 | Withdrawn | ClinicalTrials |
| NIRAPARIB | Small molecule | ovarian carcinoma | Poly [ADP-ribose] polymerase 2 inhibitor | 4.0 | - | FDA |
| OLAPARIB | Small molecule | breast cancer | PARP 1, 2 and 3 inhibitor | 3.0 | Enrolling by invitation | ClinicalTrials |
| RUCAPARIB | Small molecule | neoplasm | PARP 1, 2 and 3 inhibitor | 2.0 | Terminated | ClinicalTrials |
| OLAPARIB | Small molecule | non-small cell lung carcinoma | PARP 1, 2 and 3 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | pancreatic neoplasm | PARP 1, 2 and 3 inhibitor | 1.0 | Completed | ClinicalTrials |
| VELIPARIB | Small molecule | glioblastoma multiforme | PARP 1, 2 and 3 inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| SENAPARIB | Small molecule | breast cancer | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Completed | ClinicalTrials |
| NIRAPARIB | Small molecule | ovarian cancer | Poly [ADP-ribose] polymerase 2 inhibitor | 4.0 | Recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | neoplasm | PARP 1, 2 and 3 inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | urinary bladder cancer | PARP 1, 2 and 3 inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| NIRAPARIB | Small molecule | breast neoplasm | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Completed | ClinicalTrials |
| RUCAPARIB | Small molecule | peritoneum cancer | PARP 1, 2 and 3 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | fallopian tube cancer | PARP 1, 2 and 3 inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | breast cancer | PARP 1, 2 and 3 inhibitor | 1.0 | Completed | ClinicalTrials |
| NIRAPARIB | Small molecule | head and neck squamous cell carcinoma | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | ovarian cancer | PARP 1, 2 and 3 inhibitor | 3.0 | Withdrawn | ClinicalTrials |
| OLAPARIB | Small molecule | small cell lung carcinoma | PARP 1, 2 and 3 inhibitor | 2.0 | Not yet recruiting | ClinicalTrials |
| NIRAPARIB | Small molecule | urogenital neoplasm | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | Uveal Melanoma | PARP 1, 2 and 3 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | endometrial cancer | PARP 1, 2 and 3 inhibitor | 1.0 | Completed | ClinicalTrials |
| OLAPARIB | Small molecule | metastatic colorectal cancer | PARP 1, 2 and 3 inhibitor | 2.0 | Not yet recruiting | ClinicalTrials |
| TALAZOPARIB | Small molecule | breast cancer | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| NIRAPARIB TOSYLATE | Small molecule | ovarian carcinoma | Poly [ADP-ribose] polymerase 2 inhibitor | 4.0 | - | FDA |
| VELIPARIB | Small molecule | metastatic melanoma | PARP 1, 2 and 3 inhibitor | 1.0 | Completed | ClinicalTrials |
| NIRAPARIB | Small molecule | neoplasm | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Completed | ClinicalTrials |
| NIRAPARIB | Small molecule | metastatic colorectal cancer | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Not yet recruiting | ClinicalTrials |
| NIRAPARIB | Small molecule | cancer | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Completed | ClinicalTrials |
| PAMIPARIB | Small molecule | cancer | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | cancer | PARP 1, 2 and 3 inhibitor | 4.0 | Recruiting | ClinicalTrials |
| PAMIPARIB | Small molecule | neoplasm | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| RUCAPARIB | Small molecule | ovarian carcinoma | PARP 1, 2 and 3 inhibitor | 4.0 | - | FDA |
| VELIPARIB | Small molecule | lymphoma | PARP 1, 2 and 3 inhibitor | 1.0 | Completed | ClinicalTrials |
| VELIPARIB | Small molecule | neoplasm | PARP 1, 2 and 3 inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| VELIPARIB | Small molecule | prostate carcinoma | PARP 1, 2 and 3 inhibitor | 2.0 | Completed | ClinicalTrials |
| NIRAPARIB | Small molecule | pancreatic adenocarcinoma | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| VELIPARIB | Small molecule | testicular carcinoma | PARP 1, 2 and 3 inhibitor | 2.0 | Completed | ClinicalTrials |
| OLAPARIB | Small molecule | head and neck malignant neoplasia | PARP 1, 2 and 3 inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | fallopian tube cancer | PARP 1, 2 and 3 inhibitor | 1.0 | Completed | ClinicalTrials |
| OLAPARIB | Small molecule | Hereditary breast and ovarian cancer syndrome | PARP 1, 2 and 3 inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| NIRAPARIB TOSYLATE | Small molecule | leiomyosarcoma | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Not yet recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | small cell lung carcinoma | PARP 1, 2 and 3 inhibitor | 2.0 | Completed | ClinicalTrials |
| OLAPARIB | Small molecule | pancreatic ductal adenocarcinoma | PARP 1, 2 and 3 inhibitor | 0.5 | Recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | pancreatic adenocarcinoma | PARP 1, 2 and 3 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| RUCAPARIB | Small molecule | cervical cancer | PARP 1, 2 and 3 inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| VELIPARIB | Small molecule | skin cancer | PARP 1, 2 and 3 inhibitor | 2.0 | Completed | ClinicalTrials |
| TALAZOPARIB | Small molecule | acute myeloid leukemia | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| NIRAPARIB | Small molecule | neoplasm | Poly [ADP-ribose] polymerase 2 inhibitor | 3.0 | Active, not recruiting | ClinicalTrials |
| VELIPARIB | Small molecule | angiosarcoma | PARP 1, 2 and 3 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| RUCAPARIB | Small molecule | ovarian cancer | PARP 1, 2 and 3 inhibitor | 1.0 | Completed | ClinicalTrials |
| OLAPARIB | Small molecule | ovarian cancer | PARP 1, 2 and 3 inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | primary peritoneal carcinoma | PARP 1, 2 and 3 inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | Hereditary breast and ovarian cancer syndrome | PARP 1, 2 and 3 inhibitor | 2.0 | Not yet recruiting | ClinicalTrials |
| VELIPARIB | Small molecule | non-Hodgkins lymphoma | PARP 1, 2 and 3 inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | inflammatory breast carcinoma | PARP 1, 2 and 3 inhibitor | 1.0 | Completed | ClinicalTrials |
| NIRAPARIB | Small molecule | cervical cancer | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| NIRAPARIB | Small molecule | ovarian cancer | Poly [ADP-ribose] polymerase 2 inhibitor | 4.0 | Not yet recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | ovarian cancer | PARP 1, 2 and 3 inhibitor | 0.5 | Completed | ClinicalTrials |
| 2X-121 | Small molecule | breast carcinoma | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Withdrawn | ClinicalTrials |
| RUCAPARIB CAMSYLATE | Small molecule | prostate adenocarcinoma | PARP 1, 2 and 3 inhibitor | 3.0 | Recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | ovarian cancer | PARP 1, 2 and 3 inhibitor | 1.0 | Completed | ClinicalTrials |
| TALAZOPARIB | Small molecule | prostate cancer | Poly [ADP-ribose] polymerase 2 inhibitor | 3.0 | Recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | pancreatic ductal adenocarcinoma | PARP 1, 2 and 3 inhibitor | 2.0 | Completed | ClinicalTrials |
| NIRAPARIB | Small molecule | rectum cancer | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | cholangiocarcinoma | PARP 1, 2 and 3 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| TALAZOPARIB TOSYLATE | Small molecule | triple-negative breast cancer | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | breast carcinoma | PARP 1, 2 and 3 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| VELIPARIB | Small molecule | non-small cell lung carcinoma | PARP 1, 2 and 3 inhibitor | 3.0 | Completed | ClinicalTrials |
| OLAPARIB | Small molecule | pancreatic adenocarcinoma | PARP 1, 2 and 3 inhibitor | 3.0 | Active, not recruiting | ClinicalTrials |
| TALAZOPARIB | Small molecule | breast adenocarcinoma | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Completed | ClinicalTrials |
| VELIPARIB | Small molecule | male breast carcinoma | PARP 1, 2 and 3 inhibitor | 1.0 | Completed | ClinicalTrials |
| VELIPARIB | Small molecule | T-cell non-Hodgkin lymphoma | PARP 1, 2 and 3 inhibitor | 1.0 | Unknown status | ClinicalTrials |
| VELIPARIB | Small molecule | triple-negative breast cancer | PARP 1, 2 and 3 inhibitor | 2.0 | Completed | ClinicalTrials |
| OLAPARIB | Small molecule | Fallopian Tube Carcinoma | PARP 1, 2 and 3 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| RUCAPARIB | Small molecule | breast cancer | PARP 1, 2 and 3 inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | small cell lung carcinoma | PARP 1, 2 and 3 inhibitor | 2.0 | Terminated | ClinicalTrials |
| RUCAPARIB | Small molecule | fallopian tube cancer | PARP 1, 2 and 3 inhibitor | 1.0 | Completed | ClinicalTrials |
| NIRAPARIB | Small molecule | ovarian cancer | Poly [ADP-ribose] polymerase 2 inhibitor | 3.0 | Recruiting | ClinicalTrials |
| NIRAPARIB | Small molecule | glioblastoma multiforme | Poly [ADP-ribose] polymerase 2 inhibitor | 0.5 | Recruiting | ClinicalTrials |
| NIRAPARIB | Small molecule | breast cancer | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Terminated | ClinicalTrials |
| NIRAPARIB | Small molecule | ovarian neoplasm | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Terminated | ClinicalTrials |
| VELIPARIB | Small molecule | Ovarian Transitional Cell Carcinoma | PARP 1, 2 and 3 inhibitor | 1.0 | Completed | ClinicalTrials |
| RUCAPARIB | Small molecule | gastric cancer | PARP 1, 2 and 3 inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| PAMIPARIB | Small molecule | non-small cell lung carcinoma | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Not yet recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | serous adenocarcinoma | PARP 1, 2 and 3 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | ovarian neoplasm | PARP 1, 2 and 3 inhibitor | 2.0 | Completed | ClinicalTrials |
| RUCAPARIB | Small molecule | fallopian tube cancer | PARP 1, 2 and 3 inhibitor | 2.0 | Completed | ClinicalTrials |
| NIRAPARIB | Small molecule | prostate adenocarcinoma | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | renal cell carcinoma | PARP 1, 2 and 3 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| TALAZOPARIB | Small molecule | triple-negative breast cancer | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| PAMIPARIB | Small molecule | grade III glioma | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| TALAZOPARIB | Small molecule | breast neoplasm | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Terminated | ClinicalTrials |
| OLAPARIB | Small molecule | breast cancer | PARP 1, 2 and 3 inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| SENAPARIB | Small molecule | ovarian cancer | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| TALAZOPARIB | Small molecule | pancreatic carcinoma | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Terminated | ClinicalTrials |
| OLAPARIB | Small molecule | pancreatic carcinoma | PARP 1, 2 and 3 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| NIRAPARIB | Small molecule | urothelial carcinoma | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| VELIPARIB | Small molecule | breast carcinoma | PARP 1, 2 and 3 inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| PAMIPARIB | Small molecule | neoplasm | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Completed | ClinicalTrials |
| NIRAPARIB | Small molecule | ovarian carcinoma | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | small cell lung carcinoma | PARP 1, 2 and 3 inhibitor | 1.0 | Completed | ClinicalTrials |
| VELIPARIB | Small molecule | non-small cell lung carcinoma | PARP 1, 2 and 3 inhibitor | 2.0 | Completed | ClinicalTrials |
| NIRAPARIB | Small molecule | neoplasm | Poly [ADP-ribose] polymerase 2 inhibitor | 4.0 | - | ATC |
| RUCAPARIB | Small molecule | neoplasm | PARP 1, 2 and 3 inhibitor | 1.0 | Terminated | ClinicalTrials |
| RUCAPARIB | Small molecule | neoplasm | PARP 1, 2 and 3 inhibitor | 4.0 | - | ATC |
| RUCAPARIB | Small molecule | small cell lung carcinoma | PARP 1, 2 and 3 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | ovarian neoplasm | PARP 1, 2 and 3 inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| TALAZOPARIB | Small molecule | metastatic malignant neoplasm | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Completed | ClinicalTrials |
| NIRAPARIB | Small molecule | Ewing sarcoma | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Completed | ClinicalTrials |
| OLAPARIB | Small molecule | neoplasm | PARP 1, 2 and 3 inhibitor | 1.0 | Terminated | ClinicalTrials |
| RUCAPARIB CAMSYLATE | Small molecule | ovarian carcinoma | PARP 1, 2 and 3 inhibitor | 4.0 | - | FDA |
| VELIPARIB | Small molecule | ovarian cancer | PARP 1, 2 and 3 inhibitor | 1.0 | Completed | ClinicalTrials |
| VELIPARIB | Small molecule | breast cancer | PARP 1, 2 and 3 inhibitor | 3.0 | Active, not recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | breast cancer | PARP 1, 2 and 3 inhibitor | 2.0 | Completed | ClinicalTrials |
| OLAPARIB | Small molecule | breast cancer | PARP 1, 2 and 3 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| NIRAPARIB | Small molecule | prostate carcinoma | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| VELIPARIB | Small molecule | pancreatic adenocarcinoma | PARP 1, 2 and 3 inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| NIRAPARIB | Small molecule | breast cancer | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Terminated | ClinicalTrials |
| OLAPARIB | Small molecule | ovarian cancer | PARP 1, 2 and 3 inhibitor | 2.0 | Enrolling by invitation | ClinicalTrials |
| TALAZOPARIB | Small molecule | Hereditary breast and ovarian cancer syndrome | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| VELIPARIB | Small molecule | neoplasm | PARP 1, 2 and 3 inhibitor | 2.0 | Completed | ClinicalTrials |
| TALAZOPARIB | Small molecule | urothelial carcinoma | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | neoplasm | PARP 1, 2 and 3 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | renal cell carcinoma | PARP 1, 2 and 3 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| VELIPARIB | Small molecule | gliosarcoma | PARP 1, 2 and 3 inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| TALAZOPARIB | Small molecule | high grade ovarian serous adenocarcinoma | Poly [ADP-ribose] polymerase 2 inhibitor | 0.5 | Completed | ClinicalTrials |
| OLAPARIB | Small molecule | gastric cancer | PARP 1, 2 and 3 inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| NIRAPARIB | Small molecule | breast adenocarcinoma | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | osteosarcoma | PARP 1, 2 and 3 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| TALAZOPARIB | Small molecule | small cell lung carcinoma | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | prostate cancer | PARP 1, 2 and 3 inhibitor | 1.0 | Terminated | ClinicalTrials |
| OLAPARIB | Small molecule | prostate cancer | PARP 1, 2 and 3 inhibitor | 4.0 | Recruiting | ClinicalTrials |
| VELIPARIB | Small molecule | breast carcinoma | PARP 1, 2 and 3 inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| RUCAPARIB | Small molecule | mesothelioma | PARP 1, 2 and 3 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| TALAZOPARIB TOSYLATE | Small molecule | breast neoplasm | Poly [ADP-ribose] polymerase 2 inhibitor | 4.0 | - | FDA |
| OLAPARIB | Small molecule | disease of genitourinary system | PARP 1, 2 and 3 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | Fallopian Tube Carcinoma | PARP 1, 2 and 3 inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| VELIPARIB | Small molecule | Mantle cell lymphoma | PARP 1, 2 and 3 inhibitor | 1.0 | Unknown status | ClinicalTrials |
| RUCAPARIB | Small molecule | prostate adenocarcinoma | PARP 1, 2 and 3 inhibitor | 3.0 | Recruiting | ClinicalTrials |
| TALAZOPARIB | Small molecule | renal cell carcinoma | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| VELIPARIB | Small molecule | non-small cell lung carcinoma | PARP 1, 2 and 3 inhibitor | 1.0 | Completed | ClinicalTrials |
| OLAPARIB | Small molecule | prostate adenocarcinoma | PARP 1, 2 and 3 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| NIRAPARIB | Small molecule | small cell lung carcinoma | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | metastatic melanoma | PARP 1, 2 and 3 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | angiosarcoma | PARP 1, 2 and 3 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| NIRAPARIB | Small molecule | endometrial carcinoma | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Terminated | ClinicalTrials |
| RUCAPARIB | Small molecule | non-small cell lung carcinoma | PARP 1, 2 and 3 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| TALAZOPARIB | Small molecule | breast cancer | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Terminated | ClinicalTrials |
| VELIPARIB | Small molecule | metastatic colorectal cancer | PARP 1, 2 and 3 inhibitor | 2.0 | Completed | ClinicalTrials |
| OLAPARIB | Small molecule | soft tissue sarcoma | PARP 1, 2 and 3 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | ovarian cancer | PARP 1, 2 and 3 inhibitor | 3.0 | Active, not recruiting | ClinicalTrials |
| TALAZOPARIB | Small molecule | breast carcinoma | Poly [ADP-ribose] polymerase 2 inhibitor | 4.0 | - | FDA |
| E-7016 | Small molecule | neoplasm | PARP 1, 2 and 3 inhibitor | 1.0 | Completed | ClinicalTrials |
| OLAPARIB | Small molecule | prostate adenocarcinoma | PARP 1, 2 and 3 inhibitor | 2.0 | Unknown status | ClinicalTrials |
| TALAZOPARIB | Small molecule | renal cell carcinoma | Poly [ADP-ribose] polymerase 2 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | head and neck squamous cell carcinoma | PARP 1, 2 and 3 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| OLAPARIB | Small molecule | breast cancer | PARP 1, 2 and 3 inhibitor | 3.0 | Recruiting | ClinicalTrials |
| PAMIPARIB | Small molecule | prostate cancer | Poly [ADP-ribose] polymerase 2 inhibitor | 2.0 | Recruiting | ClinicalTrials |